Camurus appoints Chief Commercial Officer

Lund, Sweden – 14 December 2015 — Camurus (NASDAQ STO: CAMX) today announces the
appointment of Richard Jameson to the position of Chief Commercial Officer and
member of the Executive Management Team, thereby completing the recruitment
process informed in the IPO and listing prospectus. Mr. Jameson will assume his
position with Camurus during 2016, on a date to be confirmed. Richard Jameson
has broad experience from different commercial roles across a number of
specialty pharmaceutical companies, including Schering Plough, Ferring and
Indivior, where for the last three years he has been serving as Area Director
EMEA. In this role he was responsible for the leadership of a commercial
organization across Europe, the Middle-East and Africa, focusing on the opioid
dependence therapeutic area.

“It is a great pleasure to welcome Richard Jameson to join Camurus. Richard will
bring a wealth of experience to our team at a time when we are expanding our
business and starting the build-up of our commercial organization in Europe”
said Fredrik Tiberg, President and CEO, Camurus.

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to
developing and commercialising innovative and differentiated medicines for the
treatment of severe and chronic conditions. New drug products with best-in-class
potential are conceived based on the proprietary FluidCrystal® drug delivery
technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes
products for treatment of cancer, endocrine diseases, pain and addiction,
developed in-house and in collaboration with international pharmaceutical
companies. The company’s share is listed on Nasdaq Stockholm under the ticker
“CAMX”. For more information, visit www.camurus.com.

For more information:
Fredrik Tiberg, CEO and Head of Research
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
ir@camurus.com

The information in this press release is disclosed by Camurus AB in accordance
with the Swedish Securities Markets Act and/or the Swedish Financial Instruments
Trading Act. The information was submitted for publication at 08.00 a.m. on 14
December 2015.